Eden Radioisotopes has filed a construction permit application with the Nuclear Regulatory Commission for a facility to produce medical radioisotopes, primarily molybdenum-99 and lutetium-177.

The United States has lacked a reliable domestic source of Mo-99 for diagnostic imaging for decades, and has invested in infrastructure in South Africa, the Netherlands, and Belgium to assist facilities in producing the isotope using HALEU targets. These reactors are old, and there have been disruptions to the supply chain due to unplanned outages for repairs. With a 66-hour half-life, Mo-99 cannot be stockpiled.